2.1. Study Design
Cancer
CANCER
The trial was a prospective, randomized, open-label study conducted at the Vilnius University hospital “Santaros Clinics”, a Cardiology and Angiology clinic (Vilnius, Lithuania). Patients were referred from the National Cancer Institute.This study complied with the Declaration of Helsinki. The study protocol was approved by the State Medicines Control Agency and Lithuanian Bioethics Committee (protocol code ICO, 2019-04-16, No. P-19-12), and was registered on ClinicalTrials.gov on 24/07/2019 (No. NCT04030546) and on EudraCT (No. 2019-000661-20).All participants provided written informed consent.